Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

U.S. product sales were flat at $2.9 billion in the quarter and included a $65 million unfavorable impact due to U.S. health care reform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

4Q Revenues: $3.8 billion (+1%)

4Q Earnings: $1.0 billion (+10%)

FY Revenues: $15.1 billion (+3%)

FY Earnings: $4.6 billion (flat)

Comments: U.S. product sales were flat at $2.9 billion in the quarter and included a $65 million unfavorable impact due to U.S. health care reform. International product sales were up 3% to $891 million. Total product sales included a $26 million negative impact of foreign exchange. For the year, U.S. product sales increased 1% to $11.3 billion and included a $198 million unfavorable impact due to U.S. health care reform. International product sales were up 6% to $3.4 billion. Worldwide Aranesp sales were down 2% to $633 million in the quarter and down 6% to $2.5 billion for the year. Sales of Epogen were $591 million in the quarter (-16%), and decreased 2% to $2.5 billion for the year. Combined worldwide Neulasta and Neupogen sales were up 3% to $1.2 billion in the quarter, and up 4% to $4.8 billion for the year. Enbrel sales were $939 million in the quarter (+3%) and $3.5 billion for the year (+1%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters